Spring 2018 Surplus Lines Law Group Meeting Sponsored by Gardere
Complimentary Event Spans Two Days in Austin
26 April 2018
Gardere is proud to be a sponsor of the Spring 2018 Surplus Lines Law Group Meeting to be held April 26-27. Hosted by the Surplus Lines Stamping Office of Texas, the event provides an opportunity for members of the excess and surplus lines community to network with practitioners and legal counsel and discuss pending issues, legislation and interpretation of best practices. Participants will attend a forum covering trends and topics on relevant state and federal arenas.
The complimentary event will take place at the Hyatt Lost Pines in Austin, Texas. A cocktail reception and dinner will be provided, Thursday, April 26, and the business meeting will follow the morning of Friday, April 27.
To register for the event, click here.
#SLLawGroup2018
Related Insights
24 July 2025
Events
ACI's Inaugural Summit on GLP-1 Law & Policy
Foley partner Kyle Faget, co-chair of the firm’s Medical Devices Area of Focus, is speaking in American Conference Institute’s Inaugural Summit on GLP-1 Law & Policy on July 24.
23 April 2025
Tariff & International Trade Resource
What Every Multinational Company Should Know About…Tariff Strategies for Sell-Side Contracts
With the size and scope of President Trump’s tariffs continuing to shift, this is a critical time for businesses to assess their contracts and determine how increased tariff costs might adversely affect profitability, and whether there are any strategies to mitigate the losses.
22 April 2025
Health Care Law Today
Health Care Marketing: The Seventh Circuit Addresses “Referrals” Under The Anti-Kickback Statute
The case, United States v. Sorenson, addressed whether a Medicare-registered distributor violated the AKS in making payments to advertising, marketing, and manufacturing companies that worked to sell orthopedic braces to Medicare patients. The court held that such payments were not “referrals” within the meaning of the AKS because the payments were made to entities that were neither physicians in a position to refer their patients nor other decisionmakers in positions to “leverage fluid, informal power and influence” over health care decisions.